Alternative names:
SARS-CoV-2 Beta variant

Specifications for PepTivator® SARS-CoV-2 Prot_S B.1.351

Overview

PepTivators are pools of lyophilized peptides, consisting mainly of 15-mer sequences with 11 amino acids overlap. The PepTivator
®
SARS-CoV-2 Prot_S B.1.351 Mutation Pool covers selectively the mutated regions in the surface or spike glycoprotein (“S”) of the SARS-CoV-2 B.1.351 lineage (Beta variant). PepTivator SARS-CoV-2 Prot_S B.1.351 WT Reference Pool consists of the 30 homologous peptides of the Wuhan sequence and serves as a control.
In vitro
stimulation of antigen-specific T cells with PepTivator Peptide Pools causes the secretion of effector cytokines and the up-regulation of activation markers, which then allow the detection and isolation of antigen-specific T cells.

Alternative names

SARS-CoV-2 Beta variant

Detailed product information

Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was first detected in December 2019 in Wuhan, China. Since that time the virus kept mutating, leading to new virus variants. The B.1.351 lineage, also known as Beta variant, variant 501Y.V2 or VOC-202012/02, is a SARS-CoV-2 variant that was first discovered in South Africa, October 2020. The mutations of this variant affect also immune relevant parts of structural SARS-CoV-2 proteins and the respective sequences are available in GISAID, a genome data base. The mutations listed below are taken from EPI_ISL_861709. The B.1.351 lineage (Beta variant) has been found to be more infectious than former variants and has become quickly the dominant strain in South Africa.
In total there are 10 mutations in surface or spike glycoprotein (“S”) of the B.1.351 lineage (Beta variant) compared to the Wuhan variant (reference genome GenBank MN908947.3): D80A, D215G, 242 deletion, 243 deletion, 244 deletion, K417N, E484K, N501Y, D614G, A701V.
PepTivator
®
SARS-CoV-2 Prot_S Prot_S B.1.351 Mutation Pool covers selectively the mutated regions. It consists of 30 peptides of 15 aa length. The PepTivator SARS-CoV-2 Prot_S B.1.351 Mutation Pool can be used to supplement PepTivators covering the sequence of the wild-type spike glycoprotein (“S”) in order to detect immune responses towards both variants, Wuhan (wild-type) variant and B.1.351 lineage (Beta variant). PepTivator Peptide pools spanning the sequence of the spike glycoprotein (“S”) of the Wuhan (wild-type) variant are PepTivator SARS-CoV-2 Prot_S (predicted immunodominant sequence domains), SARS-CoV-2 Prot_S1 (N-terminal S1 domain) and SARS-CoV-2 Prot_S+ (part of the C-terminal S2 domain).
PepTivator SARS-CoV-2 Prot_S B.1.351 WT Reference Pool consists of the 30 homologous peptides of the Wuhan sequence and covers D80, D215, L242, A243, L244, K417, E484, N501, D614, A701 of the Wuhan variant (reference genome GenBank MN908947.3). PepTivator SARS-CoV-2 Prot_S B.1.351 WT Reference Pool serves as a control for the PepTivator SARS-CoV-2 Prot_S B.1.351 Mutation Pool. Comparison of the T cell immune response upon stimulation with mutation and reference pool can be used to analyze mutation-specific T cell responses.

Applications

The
in vitro
stimulation of SARS-CoV-2–specific CD4
+
and CD8
+
T cells with PepTivators causes secretion of effector cytokines and upregulation of activation markers, which then allow the detection and isolation of SARS-CoV-2–specific T cells:
  • Detection and analysis of antigen-specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable antigen-specific CD4+ T cells with the CD154 MicroBead Kit, or of viable CD4+ and CD8+ T cells using MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation antigen-specific CD4+ and CD8+ effector/ memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells, e.g. for research on dendritic cell vaccination.

Resources for PepTivator® SARS-CoV-2 Prot_S B.1.351

References for PepTivator® SARS-CoV-2 Prot_S B.1.351

Publications

  1. Strafella, C. et al. (2021) Case Report: Sars-CoV-2 Infection in a Vaccinated Individual: Evaluation of the Immunological Profile and Virus Transmission Risk Front Immunol (doi: 10.3389/fimmu.2021.708820)
  2. Geers, D. et al. (2021) SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees Sci Immunol (doi: 10.1126/sciimmunol.abj1750)
  3. Vallejo, A. et al.
    IFN-γ
    +
    cell response and IFN-γ release concordance after
    in vitro
    SARS-CoV-2 stimulation
    Eur J Clin Invest (doi: 10.1111/eci.13636)

Related products for
PepTivator® SARS-CoV-2 Prot_S B.1.351

9 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?